Atzeni, FabiolaMasala, Ignazio FrancescoRodríguez Carrió, JavierRíos Garcés, RobertoGerratana, ElisabettaCorte La, LauraGiallanza, ManuelaNucera, ValeriaRiva, AgostinoEspinosa Garriga, GerardCervera i Segura, Ricard, 1960-2022-02-012022-02-012021-02-162077-0383https://hdl.handle.net/2445/182875Introduction: While waiting for the development of specific antiviral therapies and vaccines to effectively neutralize the SARS-CoV2, a relevant therapeutic strategy is to counteract the hyperinflammatory status, characterized by an increase mainly of interleukin (IL)-1β, IL-2, IL-6, IL-7, IL-8, and tumor necrosis factor (TNF)-α, which hallmarks the most severe clinical cases. 'Repurposing' immunomodulatory drugs and applying clinical management approved for rheumatic diseases represents a game-changer option. In this article, we will review the drugs that have indication in patients with COVID-19, including corticosteroids, antimalarials, anti-TNF, anti-IL-1, anti-IL-6, baricitinib, intravenous immunoglobulins, and colchicine. The PubMed, Medline, and Cochrane Library databases were searched for English-language papers concerning COVID-19 treatment published between January 2020 and October 2020. Results were summarized as a narrative review due to large heterogeneity among studies. In the absence of specific treatments, the use of immunomodulatory drugs could be advisable in severe COVID-19 patients, but clinical outcomes are still suboptimal. An early detection and treatment of the complications combined with a multidisciplinary approach could allow a better recovery of these patients20 p.application/pdfengcc-by (c) Atzeni, Fabiola et al., 2021https://creativecommons.org/licenses/by/4.0/COVID-19PneumòniaCOVID-19Pneumoniainfo:eu-repo/semantics/article7082412022-02-01info:eu-repo/semantics/openAccess